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No empirical studies have defined the posttransplant
survival that would justify expansion of the Milan cri-
teria for liver transplantation of hepatocellular carci-
noma. We created a Markov model comparing the
survival benefit of transplantation for a patient with
>Milan HCC, versus the harm caused to other patients
on the waiting list.
In the base-case analysis, the strategy of transplant-
ing the patient with >Milan HCC resulted in a 44%
increased risk of death and a utility loss of 3 quality-
adjusted years of life across the pre- and posttrans-
plant periods for a nationally representative cohort of
patients on the waiting list. This harm outweighed the
benefit of transplantation for a patient with >Milan
HCC having a 5-year posttransplant survival of less
than 61%. This survival threshold was most sensitive
to geographic variations in organ shortage, with the
threshold varying from 25% (Region 3) to >72% (Re-
gions 1, 5, 7 and 9).
In conclusion, expansion of the Milan criteria will re-
quire demonstrating high survival rates for the newly
eligible patients—approximately 61% at 5 years af-
ter transplantation. In regions with less severe organ
shortage, a more aggressive approach to transplanting
these patients may be justified.
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Introduction
Early experience with liver transplantation for hepatocel-
lular carcinoma (HCC) was disappointing, with many pa-
tients developing early tumor recurrence (1). Then in 1996,
Mazaferro et al. (2) showed that when patients were care-
fully selected, transplantation of early HCC was associated
with a 75% survival after 4 years (3). This led to the de-
velopment of the Milan criteria for transplant eligibility: a
single lesion <5 cm or three lesions each <3 cm, without
gross vascular invasion or metastatic disease (4). When
these criteria are applied, posttransplant survival is simi-
lar to patients transplanted without HCC (2). In the United
States, patients with solitary HCC from 2 to 5 cm or 2–3
lesions <3 cm receive extra priority model for end-stage
liver disease (MELD) points for transplantation, increasing
their likelihood of receiving an organ (5).
Unfortunately, up to 70% of patients with HCC are diag-
nosed at advanced stages of the disease (6), and are not
suitable candidates for transplantation by Milan criteria. For
most of these patients, the currently available treatment
options are associated with little chance of cure (5,7). Fur-
thermore, the incidence of HCC in the United States is
increasing (8). This has led some authors to call for award-
ing priority MELD points to patients with tumors exceeding
Milan criteria. Yao et al. (9) have proposed a new set of cri-
teria, the University of California at San Francisco (UCSF)
criteria: solitary tumor 6.5 cm or less, no more than three
lesions with the largest being 4.5 cm or less, and a total
tumor diameter 8 cm or less, without gross vascular inva-
sion.
Given the shortage of organs for transplantation, the ques-
tion of whether to award priority points to patients with
HCC exceeding Milan but within UCSF criteria (Milan-
UCSF+) is controversial (10,11). The 5-year posttransplant
survival for patients with Milan-UCSF+ HCC has been re-
ported as anywhere from 38% to 93% (see Table 1). Such
variability across studies may be due to differential patient
selection and small numbers of patients in each study. Fur-
ther research is needed to refine these estimates, but the
question will still remain: what is the lowest acceptable
posttransplant survival at which transplantation with stan-
dard quality organs would still be justified? In other words,
what proportion of patients would have to survive 5 years
after transplantation in order for transplanting these pa-
tients to be a good use of scarce organs? No studies have
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Table 1: Five-year survival after liver transplantation for patients with HCC exceeding Milan criteria
Number of Etiology of HCC Staging Neoadjuvant 5-year
Author, year patients liver disease staging method therapy survival Ref.
























Yao 2006 32 Not listed Milan-UCSF+ Radiologic Yes 93% (43)
addressed this question in an empirical manner. We pro-
pose that this threshold can be estimated by balancing the
survival benefit and gains in life expectancy from transplan-
tation for the Milan-UCSF+ HCC patient, against the harm
caused by delaying transplantation for the other patients
on the waiting list. How much harm would be caused by
expanding the Milan criteria? The aim of this study was
to examine how transplantation of a patient with Milan-
UCSF+ HCC affects survival of patients on the waiting list
across the pre- and posttransplant periods (overall survival).
Using this approach we then determined the 5-year post-
transplant survival threshold, below which transplantation
for patients with HCC is no longer justified.
Methods
Definition of survival benefit and harm
The survival benefit of liver transplantation for the patient with Milan-
UCSF+HCC can be calculated by subtracting the area under the survival
curve without transplantation from the area under the survival curve with
transplantation (12). The harm caused to others on the waiting list, if the
Milan-UCSF+HCC patient is transplanted with a standard quality organ, de-
pends on the additional time these patients must wait for a transplant to
occur and their rate of death while waiting.
From a utilitarian perspective, optimal organ allocation will maximize the life
expectancy of the entire cohort of patients with benign and malignant liver
disease. Thus, if the benefit to the Milan-UCSF+HCC patient is greater than
the cumulative harm to the rest of the transplant waiting list, then the HCC
patient should receive the transplant.
Decision model
We constructed a Markov model, which examines the decision whether or
not to transplant a patient with Milan-UCSF+ HCC, beginning just prior to
this patient receiving the organ. The impact of this decision on the Milan-
UCSF+ HCC patient and other patients on the waiting list was weighted as
follows:
Milan − UCSF + HCC = 1/(N + 1),
Other patients = 1 − 1/(N + 1),
where N = the number of patients on the waiting list before the Milan-
UCSF+ HCC patient is listed. For example, if there were three other patients
on the list then the weighting would be:
Milan − UCSF + HCC = 1/(3 + 1) = 0.25,
Other patients = 1 − 1/(3 + 1) = 0.75.
Thus, the cumulative harm to patients on the waiting list is proportional to
the number of patients on the list.
840 American Journal of Transplantation 2008; 8: 839–846
Benefits and Harms of Expanding Milan Criteria
Study endpoints
Both the Milan-UCSF+ patient and the waiting list patients were followed
for 10 years in the model. Thus the survival benefit for the Milan-UCSF+
patient and the harm to the waiting list patients were measured over the
10 years, which included the pre- and posttransplant periods. This time
horizon was chosen in an effort to balance the need for allocation policies,
which maximize long-term survival and the limited long-term survival data
for patients with Milan-UCSF+ HCC.
Model assumptions
Prior to the beginning of the model, the patient with Milan-UCSF+ HCC was
assumed to have received an increase in MELD exception points every 3
months, as is current practice with patients meeting Milan criteria (13). The
model begins once the Milan-UCSF+ HCC patient is first in line for the next
available organ. If this patient is transplanted, then the other patients on
the waiting list all wait for one extra organ arrival cycle and are subjected
to the extra risk of death during this time period. This scenario is displayed
in Figure 1. The increase in harm caused by transplanting the Milan-UCSF+
HCC patient therefore depends on the number of patients on the waiting
list, their waiting list and posttransplant mortality rates and the organ arrival
rate.
Because the death rates and transplantation rates vary substantially by
MELD scores, the waiting list patients were divided into subgroups with
MELD scores of 11–20, 21–30 and >30. Separate Markov processes were
developed for each of these groups as previously described (14), as well as
for patients with HCC within Milan criteria who currently receive automatic
MELD upgrades to 22 and extra points every 3 months thereafter (13). Pa-
tients with MELD scores <11 were excluded, since their mortality rates and
transplant rates are negligible (15). Patients with MELD exceptions other
than HCC were not explicitly modeled, since they represent a small and


















Figure 1: Influence diagram describing the structure of the
model. If the patient with hepatocellular carcinoma exceed-
ing Milan criteria but within University of California San Fran-
cisco criteria (Milan-UCSF+ HCC) receives a transplant, all the
patients in the waiting list cohort start off in an initial wait-
ing state and progress to the pretransplant state once the
first organ arrives. If the Milan-UCSF+ patient does not re-
ceive a transplant, then all the waiting list patients start off in
the pretransplant state. The solid black arrow indicates that
death can occur from any state.
The Markov cycle length was 1 day, and survival was adjusted for quality
of life based on utilities as described below. Discounting of quality-adjusted
life expectancy was performed at a rate of 3% per year. All analyses were
performed using TreAge Pro v2006 1.2 (TreAge Software, Williamstown,
MA).
Data sources
National averages for waiting list size, organ arrival rates, mortality rates on
the list, dropout rates, time to transplantation and posttransplant survival
were obtained from the most recent report of the Organ Procurement and
Transplantation Network (www.optn.org) (17). Table 2 displays all of the
variables used in the model, the base-case values, ranges and sources of
data. Annual probabilities were converted to daily probabilities using a linear
decay function (18).
Waiting list variables
The waiting list size and organ arrival rate in the base-case analysis was the
national average per blood group and donation service area (DSA), excluding
patients with MELD scores <11. Dropout from the waiting list was mod-
eled separately for HCC patients within Milan criteria, since most deaths
occur after waiting list removal. The median time-to-transplant was used
to calculate the probability of getting a transplant rather than the median
waiting times, since the latter excludes time spent on the list as inactive
status (17). The same posttransplant survival rates were used for all wait-
ing list patients, as these do not vary substantially by MELD score (12) and
it is unclear whether MELD predicts posttransplant survival over the long
term (19). All calculated variables were similar to those used in previously
published models of the liver transplant organ allocation system (14,20).
For the distribution of MELD scores on the waiting list, registration MELD
scores were used in the base-case analysis (12) and a cross-section of the
average waiting list (21) was analyzed on sensitivity analysis.
Milan-UCSF+ HCC variables
In the scenario where the patient with Milan-UCSF+ HCC does not receive
a transplant, we assumed that patient would receive standard care including
transarterial chemoembolization (TACE), with 5-year survival rates of 10%
in the base-case analysis (7,22–24). In the scenario where the patient with
Milan-UCSF+HCC receives a transplant, the 5-year survival was varied as
the primary endpoint of the study. Since most HCC recurrences occur within
the first 2 years (25), we assumed a low mortality rate between years 5 and
10 posttransplantation of 2% per year.
Utilities
Quality of life for pre- and posttransplant patients was determined by a sys-
tematic review of the literature using the search algorithm (quality of life
OR utilities) AND liver transplantation (n = 390). Articles prior to a 1998
systematic review (26) were excluded, yielding 210 abstracts, which were
reviewed. Studies were selected for data abstraction if they used utility
assessment techniques and determined quality of life pre- and posttrans-
plantation within the same patient population (n = 3 studies) (27–29). Since
no studies have directly compared the quality of life for Milan-UCSF+HCC
patients versus other patients on the waiting list, they were assumed to
be equivalent for the base-case analysis. In the sensitivity analysis, we ana-
lyzed a range of plausible assumptions based on the quality of life literature
in patients with cirrhosis (27–29).
Model calibration and sensitivity analysis
We examined model predictions for transplant rates and survival in order
to ensure the model structure was calibrated and aligned with expected
rates. This involved comparison of the 90-day outcomes for patients in the
model, with the 90-day outcomes of a waiting list cohort reported by the
OPTN (17). The small numbers of patients in the OPTN cohort limited reliable
comparison for all but the MELD 11–20 group (n = 6369), among whom 90%
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Table 2: Variables utilized in constructing the model
Variable Base-case values Range Source
Waiting list size (N)1 58 11–86 (17)
Organs arriving per year1 30 18–38 (17)
Waitlist mortality (deaths/1000 patient-years) MELD 11–20 135 100–150 (17)
Waitlist mortality (deaths/1000 patient-years) MELD 21–30 693 550–900 (17)
Waitlist mortality (deaths/1000 patient-years) MELD >30 3500 2992–5000 (17)
Waitlist mortality (deaths/1000 patient-years) HCC (within Milan) 237 150–300 (17)
HCC (within Milan) death or dropout (probability/year) 31% 20–50% (44–46)
HCC (within Milan) death after dropout (probability/year) 46% 20–71% (45,47)
Median time-to-transplant (days) MELD 11–20 1000 500–1200 (17)
Median time-to-transplant (days) MELD 21–30 100 56–162 (17)
Median time-to-transplant (days) MELD >30 24 12–88 (17)
Median time-to-transplant (days) HCC (within Milan) 90 32–145 (17)
Proportion of list with MELD 11–202 63% 55–70% (12,17)
Proportion of list with MELD 21–30 19% 10–20% (12,17)
Proportion of list with MELD >30 8% 5–10% (12, 17)
Proportion of list with HCC (within Milan) 10% 5–15% (17,44)
Posttransplant survival waiting list patients (probability/5 years) 72% 70–75% (32)
Pretransplant quality-of-life utility 0.53 0.51–0.61 (27–29)
Posttransplant quality-of-life utility 0.62 0.61–0.63 (27–29)
Pretransplant quality-of-life utility for patients with Milan-UCSF+ HCC 0.53 0.45–0.6 (27–29)
5-year survival of Milan-UCSF+ HCC patients treated by TACE only 20% 1–30% (7,22–24)
Time horizon (years) 10 5–15 N/A
1Per donation service area and blood group. MELD = model for end-stage liver disease; HCC = hepatocellular carcinoma; TACE =
transarterial chemoembolization; Milan-UCSF+ = patients with HCC beyond Milan criteria but meeting University of California San
Francisco criteria.
2Proportions are excluding patients with MELD <11.
were still waiting, 6% were transplanted and 4% had died or dropped out
after 90 days. This compared well with the model output for the waiting list
cohort with MELD 11–20, among whom 90% were still waiting, 5.5% were
transplanted and 4.5% had died or dropped out after 90 days, indicating that
the model was well calibrated.
The base-case analysis was performed using national averages, and two-
way sensitivity analysis was performed comparing the ranges of all variables
with the range of possible posttransplant survival for the Milan-UCSF+ HCC
patient. Because organ arrival rates at DCAs across the country are corre-
lated with size of the waiting list (15), it is difficult to present and interpret
the sensitivity analysis on these variables. Therefore, we captured these
variables by repeating the analysis for each region of the country. In some
regions the model output led to a survival threshold higher than that of
the general transplant population. This is called the ‘aggregation problem’
of resource allocation, whereby in some circumstances a higher aggregate
survival could be achieved by sacrificing a few to save the majority (30).
Since public opinion and ethical theory overwhelmingly reject this violation
of equity (30,31), we set an upper limit for the survival threshold at 72%
at 5 years, which is the average survival for the general transplant popula-
tion (32). We also repeated the analysis by blood group, another proxy for
variations in organ shortage.
Finally, we considered the impact of changes in allocation policy, such as
capping the MELD exception points at 30 for patients with Milan-UCSF+
HCC. Such a policy would mean that these patients would never be trans-
planted ahead of patients with lab MELD scores above 30. This analysis
was performed by excluding patients with MELD >30 from the waiting list
cohort.
Please refer to our supplemental methods at http://www.blackwell-
synergy.com/ doi/abs/10.1111/j.1600-6143.2007.02138.x. (publisher’s host-
ing address).
Results
In the base-case analysis, with a waiting list size of
58 per blood group and DSA based upon national aver-
ages, the strategy of transplanting the patient with Milan-
UCSF+HCC increased the risk of a death occurring among
the waiting list cohort by 44%. This higher mortality risk
translated into a loss of three quality-adjusted life-years
(QALYs) for the entire cohort. The amount of harm varied
by region of the country depending on severity of organ
shortage, from a 16% mortality risk and 1.1 QALYs lost in
Region 3 to a 100% mortality risk and 4.9 QALYs lost in
Region 5. While this aggregate harm was substantial, the
harm to individual patients was much smaller and varied
by MELD score, as shown in Table 3. These harms to the
waiting list cohort were offset by the survival benefit of
transplantation for a Milan-UCSF+ patient, whose 5-year
posttransplant survival exceeded 61%, assuming a 5-year
Table 3: Harm caused to individual patients on the waiting list
when the patient with Milan-UCSF+ HCC receives an organ1
Increase in Quality-adjusted
Patient mortality risk days of life lost
subgroup (per patient) (per patient)
HCC within Milan 0.4% 10
MELD 11–20 0.1% 3
MELD 21–30 1.1% 27
MELD >30 4.2% 108
1Based on national averages for organ arrival rate.
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Figure 2: Five-year survival threshold by United Network for
Organ Sharing (UNOS) region of the country, below which the
benefit of liver transplantation for patients with Milan-UCSF+
HCC is outweighed by the harm caused to other patients.
survival with TACE alone of 10%. In other words, expand-
ing Milan criteria would require a 5-year posttransplant sur-
vival of 61% in order to outweigh the harm caused to other
patients on the waiting list.
On sensitivity analysis, this threshold value for the 5-year
posttransplant survival showed significant variability de-
pending on the severity of organ shortage. For example, in
the region with the least severe organ shortage (Region 3),
a 5-year survival as low as 25% could be permitted before
the cumulative harm to the waiting list patients outweighed
the survival benefit for the Milan-UCSF+ HCC patient. In
the regions with the most severe organ shortage (Regions
1, 5, 7 and 9), a 5-year survival greater than or equal to
the general transplant population (72%) was necessary to
maintain this balance. Figure 2 shows the survival thresh-
olds for each region of the country. The results were also
sensitive to the distribution of MELD scores on the wait-
ing list, another function of geographic variation. When the
waiting list was composed of only 15% of patients with
MELD scores >20, the 5-year survival threshold for trans-
planting the Milan-UCSF+HCC patient decreased to 38%
as shown in Figure 3. Finally, the results were sensitive
to blood group, another proxy for organ shortage. When
the waiting list was composed of only blood group O, the
survival threshold for transplanting the Milan-UCSF+HCC
patient was 68% at 5 years compared with 38% at 5 years
when the waiting list was composed of only patients with
blood group AB.
The results were fairly robust to uncertainty surrounding
the clinical variables which are unaffected by geographic
disparities. The 5-year survival of a Milan-UCSF+ HCC pa-
tient treated with TACE alone (set at 10% in the base-case
analysis) was the most influential in affecting the thresh-
old for 5-year survival, causing the survival threshold for
justifying transplantation to vary from 51% to 72%, as
shown in Figure 4. Thus, as multimodality treatments for

































Figure 3: Sensitivity analysis demonstrating the impact of
proportion of patients on the waiting list with model for end-
stage liver disease (MELD) scores >20, on the 5-year post-
transplant survival threshold for patients with Milan-UCSF+
HCC. The survival threshold is the intersection between the
black- and white-shaded areas and equals the posttransplant
survival at which the benefit of transplantation is outweighed
by the harm caused to other patients.
HCC continue to improve, a higher posttransplant survival
will be required to justify the harm caused to other patients
on the waiting list. Varying the time horizon from 5 to 15
years caused the survival threshold to vary from 72% (time
horizon of 5 years) to 54% (time horizon of 15 years). Fi-
nally, the uncertainty about quality of life for patients with
Milan-UCSF+ HCC resulted in only minor changes in the
survival threshold, from 57% to 65% across a range of plau-
sible assumptions. None of the other variables affected the
posttransplant survival threshold by more than 5%.
Milan-UCSF+ HCC 

































Figure 4: Sensitivity analysis demonstrating the impact of
survival with nontransplant therapies (such as transarterial
chemoembolization) on the 5-year posttransplant survival
threshold for patients with Milan-UCSF+ HCC.
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We then analyzed the potential impact of changing UNOS
rules so that patients with Milan-UCSF+ HCC would have
their MELD exception points capped at 30. When wait-
ing list patients with MELD scores >30 were excluded
from the model, the survival threshold for transplanting the
Milan-UCSF+ HCC patient dropped substantially to 35% at
5 years.
Discussion
We examined the posttransplant survival needed to jus-
tify expanding Milan criteria for transplantation of patients
with HCC. While the issue has raised significant debate,
to our knowledge this is the first quantitative examina-
tion of the tradeoffs between the benefits of transplant-
ing patients with HCC exceeding Milan criteria and the
harms incurred by delaying transplantation for other pa-
tients on the waiting list. We found that for the average
patient with HCC exceeding Milan criteria, a 5-year post-
transplant survival of 61% or more would be needed for the
benefit of transplantation to be outweighed by the harm
caused to other patients on the waiting list. These results
fill an important gap in the debate over expanding the Mi-
lan criteria for transplanting HCC. Although more research
is still needed to improve the prediction of survival of pa-
tients with HCC after liver transplantation, this study pro-
vides empiric evidence for a survival threshold below which
MELD exception points for transplantation should not be
awarded.
Although allocation policy is usually debated on the national
level, most organ distribution is local. We found wide vari-
ations by region of the country in the lowest acceptable
posttransplant survival for a patient with HCC, from 25% to
72% at 5 years depending on the severity of organ short-
age. Our results were also sensitive to the proportion of
patients on the waiting list with MELD scores >20, also a
function of geographic variations in organ shortage. These
findings are consistent with a recent analysis demonstrat-
ing a 4-fold difference in liver transplantation rates across
regions (15). In regions with more organs available for
transplantation, the harm caused by taking one extra or-
gan is smaller. A reorganization of the transplant regions
might reduce these disparities (33), but this may not be
politically feasible. One approach to dealing with these dis-
parities would be to expand Milan criteria in some regions
but not others. We propose that a selective expansion of
criteria may be justified in regions with less severe organ
shortage. This demonstration project could yield important
data for improving the prediction of posttransplant survival
in these patients. Alternatively, MELD exception points for
patients with HCC exceeding Milan but within UCSF crite-
ria could be capped at 30. This would mean that the prob-
ability of transplantation for these patients would depend
upon the number of other patients on the waiting list with
lab MELD scores of >30, and dropout from the list would
be high in areas of the country with the most severe organ
shortage. Either of these approaches would limit harm to
other patients on the waiting list, though they could also be
seen as exacerbating current geographic inequalities in ac-
cess to transplantation. The ethical implications of these
proposals warrant further discussion by the transplant
community.
While this is the only study to address this question, there
are several limitations and caveats to consider. First, this
study only looked at the harm of assigning MELD excep-
tion points for patients with Milan-UCSF+ HCC. We did
not consider transplantation with marginal quality organs,
which is an alternative that deserves further study. Second,
the study assumed that long-term posttransplant survival
does not vary substantially by pretransplant MELD score.
If expanding the Milan criteria caused the waiting list co-
hort to be transplanted at higher MELD scores, their post-
transplant survival could be slightly lower, resulting in harm
not measured by the model. Third, as with any modeling
study our findings are limited by the quality of the available
literature. However, aside from geographic variations in or-
gan shortage our findings were robust to sensitivity anal-
ysis for almost all variables. The most influential variable
was the survival after TACE alone for a patient with Milan-
UCSF+ HCC. As multimodal treatments for HCC continue
to improve (23,34), a higher posttransplant survival will be
needed to justify liver transplantation in these patients. De-
spite recent advances in nontransplant therapies, only a
third of candidates for curative therapy are being treated
(35). Deciding not to transplant these patients does not
mean giving up on them; more aggressive treatment is
still warranted. Finally, translating these results into clini-
cal practice is limited by the current ability to accurately
predict survival after transplantation for individual patients
with HCC exceeding Milan criteria. A recent study showed
that only 44% of tumors are accurately staged on pretrans-
plant imaging (36), thus limiting the ability of tumor stage
to predict prognosis. In the future, new methods for pre-
dicting survival such as the use of genomics or proteomics
will hopefully improve upon this accuracy (37). For now,
the limited supply of organs forces physicians to make
rationing decisions using the available data. This study
provides an analytic framework for making these difficult
decisions.
In conclusion, we show that transplanting patients with
HCC exceeding Milan criteria would cause significant harm
to the other patients on the waiting list. This finding
does not mean that expansion of Milan criteria should not
be performed, nor that individual centers should cease their
efforts to improve transplant outcomes for these patients.
Rather, our results suggest that in terms of national policy,
expansion of criteria would require 5-year posttransplant
survival rates of approximately 61% in order to outweigh
the harm to other patients. Since most centers currently
report survival rates below this threshold, it may be pre-
mature at this time to expand Milan criteria on a national
level.
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